Cambridge - a city where cancer innovations can thrive 🌱 From therapeutics to diagnostics and our mission to equip cancer scientists with the best research tools, the University of Cambridge and Cambridge Enterprise provide one of the best entrepreneurial ecosystems in the world. A privilege to be alongside such a stellar list of spinout companies making such a difference to the #cancerresearch field. ----------------------------------------------------------------------------------- See why updated tools are needed for cancer research at www.verinnogen.com
Introducing 10 Cambridge spinouts changing the story of cancer. 🌟 A brilliant idea for helping cancer patients is just that - an idea - until it is put into practice. Turning research into something that can improve patient outcomes and benefit healthcare systems around the world is not easy. At Cambridge Enterprise, we support spinouts from the University of Cambridge through their commercialisation journey. Being part of the UK’s leading life sciences cluster provides plenty of inspiration, access to investors and talent, and the guidance of others who have gone before. Meet 10 of our spinouts, all committed to making a real difference: • T-Therapeutics Ltd • Concr • 52North - creators of Neutrocheck® • PhoreMost Ltd • STORM Therapeutics Limited • Verinnogen • Spirea • biomodal • PharmEnable Therapeutics • Astex Pharmaceuticals 👉🏼 Read more about how they are are driving the future of cancer treatment: https://vist.ly/3mj67du #CancerResearch #Healthcare #LifeSciences #UniversityOfCambridge #Innovation
Executive Chair and Director
2dGreat work Isaac - good to see Verinnogen on this list.